Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q3 2020 Results - Earnings Call Transcript

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc.

Applied DNA Reports Fiscal Third Quarter 2020 Financial Results

Applied Dna Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks Showing Market Leadership: Applied Dna Sciences Earns 93 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Market Leadership: Applied Dna Sciences Earns 93 RS Rating

Applied DNA Sciences, Inc. (NASDAQ: APDN) shares are trading higher after the company announced the FDA granted an Emergency Use Authorization amendment that increases the company's COVID-19 diagnostic kit testing capacity through the use of automated RNA extraction.

Why Applied DNA Sciences' Stock Is Trading Higher Today

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences Inc.

FDA Approves EUA Amendment Increasing Applied DNA’s COVID-19 Diagnostic Kit Testing Capacity Through Use of Automated RNA Extraction and Expands Supported Platforms

Applied DNA to Report Fiscal 2020 Third Quarter Financial Results After Market Close on August 6, 2020

Applied DNA Sciences Inc (NASDAQ: APDN) shares are advancing strongly Friday following the release of positive preclinical data for its partnered coronavirus vaccine candidate.

Applied DNA Surges On Encouraging Coronavirus Vaccine Data

Applied DNA and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the appointment of Mr. Sanjay Hurry to Executive Director of Investor Relations and Corporate Communications for the company. In this role, Mr. Hurry will oversee the Company’s outreach with the investment

Applied DNA Appoints New Head of Investor Relations and Corporate Communications

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #APDN--Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the formation of a wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), dedicated to the commercial development of its tests in Virology, for the detection of COVID-19, and in Oncology, for th

Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment

Shares of Applied DNA Sciences Inc (NASDAQ: APDN), which is in the race to develop a vaccine for the novel coronavirus, offer an attractive buying opportunity, according to H.C.

Applied DNA Analyst Says Coronavirus Testing, Vaccine Work Could Drive Major Upside

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, is set to join the Russell Microcap® Index (the “Index”) at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the U.S. mark

Applied DNA Sciences Set to Join Russell Microcap Index

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2020 Results - Earnings Call Transcript

Applied DNA Sciences, Inc. (NASDAQ: APDN) shares are trading higher after the company announced it has received FDA emergency use authorization for its coronavirus diagnostic assay kit.

Why Applied DNA Sciences Stock Is Trading Higher Today

Applied DNA Sciences Inc. (NASDAQ: APDN) shares made an incredible gain on Thursday after the company announced it had received an update from the U.S.

Why This FDA Update Is Huge for Applied DNA Sciences

Shares of Applied DNA Sciences Inc. [: apdn] soared 66.2% in premarket trading on Thursday after the company announced emergency use authorization from the Food and Drug Administration for its COVID-19 test.

Shares of Applied DNA Sciences jump 66% on regulatory authorization of its COVID-19 test

Applied DNA Sciences Inc. (NASDAQ: APDN) shares shot up on Monday after the company announced an update to its COVID-19 vaccine program.

Applied DNA’s Vaccine Program Could Be a Big Hit

Applied DNA Sciences Inc (NASDAQ: APDN) shares are rallying to a six-month high following an update from the company regarding its COVID-19 vaccine program.

Applied DNA Says Results From Animal Testing of Coronavirus DNA Vaccines 'Beyond Expectations'

Applied DNA Sciences (NASDAQ: APDN) shares are trading higher on Wednesday. The company announced it shipped its Coronavirus Linear DNA vaccine candidates to its Italian development partner to begin preclinical animal testing.

Why Applied DNA Sciences Is Trading Higher Today

Applied DNA Sciences Inc. (NASDAQ: APDN) is the newest company to see a big boost riding the coronavirus wave.

Applied DNA Sciences Is the Newest Coronavirus Stock

Altimmune

BioNTech SE

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Vaxart

The outbreak of COVID-19 caused by the new coronavirus SARS-CoV-2 is roiling the global economy.

8 Biotechs With Coronavirus Vaccines In Development

Applied DNA Sciences Inc (NASDAQ: APDN) shares gapped higher Monday after the DNA manufacturing company announced an update to its COVID-19 vaccine development partnership.

Applied DNA, Takis Biotech Partner To Design COVID-19 Vaccines For Animal Testing

Applied DNA Sciences, Inc. (APDN) CEO Jim Hayward on Q1 2020 Results - Earnings Call Transcript

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2019 Results - Earnings Call Transcript

A share offering Wednesday sent Applied DNA Sciences Inc. (NASDAQ: APDN) stock back down, giving back a huge one-day gain that followed news of a breakthrough in its leather tracking technology.

News for Applied DNA Sciences Stock (APDN)